1Fragnfin during Instability in Coronary Artery Disease (FRISC) study group. Low-molecular-weight heparin during instability in coronary artery disease. Lancet, 1996,347:561-568. 被引量：1
2Klein W, Buchwald A, Hillis SE, et al. Comparison of low- molecular-weight heparin with unfractionated heparin acutely and with placebo for 6 weeks in the management of unstable coronary artery disease. Fragmin in unstable coronary artery disease study (FRIC) . Circulation, 1997,96:61-68. 被引量：1
3Comparison of two treatment durations (6 days and 14 days) of a low molecular weight heparin with a 6-day treatment of unfraetionated heparin in the initial management of unstable angina or non-Q wave myocardial infarction : FRAX. I.S. ( FRAxiparine in Ischaemic Syndrome). Eur Heart J, 1999,20 : 1553-1562. 被引量：1
4Cohen M, Demers C, Gurfinkel EP, et al. A comparison of low- molecular-weight heparin with unfract/onated heparin for unstable coronary artery disease. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q-Wave Coronary Events Study Group. N Engl J Med, 1997,337:447-452. 被引量：1
5Antman EM, McCabe CH, Gurfinkel EP, et al. Enoxaparin prevents death and cardiac ischemic events in unstable angina/ non-Q-wave myocardial infarction. Results of the thrombolysis in myocardial infarction (TIMI) llB trial. Circulation, 1999,100: 1593-1601. 被引量：1
6FRagmin and Fast Revascularisation during InStability in Coronary artery disease Investigators. Invasive compared with non-invasive treatment in unstable coronary-artery disease: FRISC Ⅱ prospective randomised multicentre study. Lancet, 1999,354:708- 715. 被引量：1
7Wallentin L, Bergstrand L, Dellborg M, et al. Low molecular weight heparin (dalteparin) compared to unfractionated heparin as an adjunct to rt-PA (alteplase) for improvement of coronary artery patency in acute myocardial infarction-the ASSENT Plus study. Eur Heart J, 2003,24:897-908. 被引量：1
8Antman EM, Morrow DA, McCabe CH, et al. Enoxaparin versus unfractionated heparin with fibrinolysis for ST-elevation myocardial infarction. N Engl J Med ,2006 ,354 :1477-1488. 被引量：1
9Fifth Organization to Assess Strategies in Acute Ischemic Syndromes Investigators. Comparison of fondaparinux and enoxaparin in acute coronary syndromes. N Engl J Med, 2006, 354 : 1464-1476. 被引量：1
10Yusuf S, Mehta SR, Chrolavicius S, et al. Effects of fondaparinux on mortality and reinfarction in patients with acute ST-segment elevation myocardial infarction : the OASIS-6 randomized trial. JAMA, 2006,295:1519-1530. 被引量：1
